Overview
VSTM market data
Price History
VSTM price chart · 1M
- O
- 6.85
- H
- 7.02
- L
- 6.84
- C
- 6.89
- Vol
- 74,916.00
- Source
- US equities market feed
- Observed
- Aug 21, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $6.85
- Previous Close
- $6.82
- Day High
- $7.02
- Day Low
- $6.84
- 52 Week High
- $7.86
- 52 Week Low
- $3.43
- 7 Day Return
- +4.63%
- 30 Day Return
- +16.58%
- 90 Day Return
- +58.03%
- 1 Year Return
- +21.30%
- Daily Notional Volume
- $516.2K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$3.02 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.48 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -391.2% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $3.43 – $11.25 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $586.1M · P/B 10.17 · P/S 11.82.
Company News
Mizuho Maintains Outperform on Verastem, Lowers Price Target to $13Benzinga · Aug 11, 2026, 11:48 AM
Guggenheim Maintains Buy on Verastem, Lowers Price Target to $12Benzinga · Aug 7, 2026, 4:46 PM
Verastem shares are trading higher after the company reported better-than-expected Q2 financial results.Benzinga · Aug 7, 2026, 12:40 PM
8-K filing — Verastem, Inc. (VSTM)SEC EDGAR · Aug 6, 2026, 11:33 PM
Verastem Q2 Adj. EPS $(0.35) Beats $(0.43) Estimate, Sales $25.078M Beat $23.093M EstimateBenzinga · Aug 6, 2026, 8:05 PM
Verastem Oncology Doses First Participant In Its TARGET-D 203 Phase 2 Study Of VS-7375 To Treat Metastatic Colorectal CancerBenzinga · Jul 28, 2026, 8:02 PM
12 Health Care Stocks Moving In Thursday's After-Market SessionBenzinga · Jul 23, 2026, 9:10 PM
Verastem Oncology Doses First Patient In Phase 2 Trial Of VS-7375 For KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer And Untreated Asymptomatic Untreated Brain MetastasesBenzinga · Jul 22, 2026, 8:02 PM
These 7 Small Caps Are on Fire as the Second Half Begins: Here’s WhyBenzinga · Jul 21, 2026, 7:52 PM
RBC Capital Maintains Outperform on Verastem, Lowers Price Target to $14Benzinga · Jul 7, 2026, 4:25 PM